In Vivo Regulation of Human Glutathione Transferase GSTP by Chemopreventive Agents

Colin J. Henderson, Aileen W. McLaren, and C. Roland Wolf

Abstract

Relatively little progress has been made in determining the in vivo regulation of glutathione S-transferase P (GSTP), particularly the human enzyme hGSTP1, despite being identified as a significant factor in carcinogenesis and development of drug resistance in tumor cell lines. Here, we report the characterization of a transgenic reporter mouse that reveals how hGSTP1 is regulated in vivo by chemopreventive agents. Basal expression was found in crypts and villi of the small and large intestine, bronchial epithelial cells, the epidermis and hair follicles, gall bladder epithelium, choroid plexus, and biliary epithelium. Expression was induced in different tissues by the antioxidant chemopreventive agents ethoxyquin and butylated hydroxyanisole. However, genetic deletion of the Nrf2 transcription factor, which directs central genetic programs of detoxification and protection against oxidative stress, increased rather than attenuated GSTP1 expression. In vitro investigations with mouse embryonic fibroblasts revealed factors, in addition to Nrf2, that control the expression of GSTP1, offering further insights into regulation. The new reporter mouse described here provides a useful tool to gain deeper insights into the mechanisms of action of chemopreventive compounds and other environmental agents. Cancer Res; 74(16): 1-10. ©2014 AACR.

Introduction

The glutathione S-transferases (GST) comprise a family of dimeric phase II drug metabolizing enzymes (EC 2.5.1.18) whose principal function is to catalyze the conjugation of reduced glutathione to reactive electrophiles as part of a cellular adaptive response to chemical toxins and oxidative stress (1). Glutathione S-transferase P (GSTP) has been reported to be significantly elevated in a range of animal and human tumor types, although the role of this enzyme in the tumorigenic process is still unclear; indeed, the endogenous roles of GSTP have yet to be fully elucidated (2, 3). Cell lines made resistant to toxic chemicals, including anticancer drugs, express high levels of GSTP (4); likewise, cell lines in which GSTP is overexpressed are found to be resistant to a range of drugs and chemicals (5), even though many of these compounds are not known to be substrates of the enzyme. It seems, therefore, that GSTP is likely to have actions that are not mediated by its primary catalytic function (6). This is supported by a growing body of information that suggests that GSTP can associate with kinases involved in signaling cellular responses to stress [e.g., Jun N-terminal kinase (JNK), apoptosis signal-regulating kinase (ASK1)], inhibiting kinase function and suppressing apoptosis (7, 8). Furthermore, GSTP has been shown to play a role in protein glutathionylation and to be essential for the regeneration of the active site cysteine in the 1-Cys peroxiredoxin Prdx6 (9).

Knockout mice lacking GSTP display no overt phenotype because of the absence of the enzyme but have increased susceptibility to chemically induced skin and lung tumors (10, 11) and are almost completely resistant to the hepatotoxic effects of acetaminophen (12). Furthermore, when GstP null mice are crossed to the APCMin line, a marked increased incidence of colonic adenomas is observed. These, like those in humans, are located in the rectal area of the large intestine, identifying the GstP null × APCMin hybrid as a model that closely recapitulates human colorectal cancer (13).

The regulation of GSTP expression has been studied extensively in mouse and rat, but less so in humans (14, 15). We and others have previously characterized the human GSTP1 promoter in vitro, identifying a number of elements through which transcription of the gene is induced or repressed (16, 17). In particular, it contains an AP-1 site (position −73 to −54) that has been extensively characterized in a multidrug-resistant derivative (VCREMS) of the breast cancer cell line MCF-7 (18). The identification and characterization of an antioxidant response element (ARE; ref. 19), which potentially overlaps with AP-1 regulatory sequences, raises the possibility that the hGSTP1 gene may also be regulated by the Nrf2/KEAP1 system (20).

To gain further insights into the in vivo regulation of GSTP, we have generated a transgenic mouse model containing the
entire human GSTP1 gene, plus 2.5 kb of promoter region, fused in-frame to lacZ and cloned into the ROSA26 locus (21). We now report that this mouse line recapitulates the known pattern of GSTP expression in man and demonstrate for the first time that the expression level of the human gene can be profoundly induced by exogenous factors such as cancer chemopreventive agents. These data provide detail on how environmental factors influence cancer susceptibility.

Materials and Methods

Chemicals

All chemicals were obtained from Sigma Fine Chemicals unless otherwise stated. Mirsky’s solution was purchased from National Diagnostics, AGTC Bioproducts.

Generation of [hGSTP1]LacZROSA26 mice

hGSTP1::LacZROSA26 mice were generated by Taconic Artemis, using approximately 500 bp of the 5’-UTR and the entire GSTP1 gene fused to LacZ (Fig. 1). This genomic sequence was fused in-frame to β-galactosidase, and the whole construct cloned into the ubiquitously transcriptionally active ROSA26 region in order to optimize the chances of generating a mouse line in which the expression of the human GSTP gene is faithfully recapitulated. This construct was targeted to the ROSA26 region in C57BL/6 embryonic stem (ES) cells by homologous recombination. The line was maintained in the hemizygous state by crossing to C57BL/6 (wild-type) mice and the presence of the genetic alteration was verified by PCR. hGSTP1::LacZROSA26 Nrf2+/− mice were generated by crossing hGSTP1::LacZROSA26 mice with Nrf2−/− mice (22), obtained originally from the laboratory of Prof. M. Yamamoto and subsequently back-crossing to C57BL/6 for 6 generations. It is important to note that the strategy used to generate the Nrf2 null mouse replaced the C-terminal half of Nrf2 with LacZ, potentially confounding data generated in crosses with the hGSTP1::LacZROSA26 line. However, neither basal nor induced reporter activity was detected in any of the tissues examined during prior testing of the Nrf2 null mice for LacZ expression in our laboratory (data not shown), so we are confident that the LacZ activity detected in hGSTP1::LacZROSA26 (Nrf2−/−) mice is derived from the reporter driven by hGSTP1 regulatory elements.

Mice were kept in open-top cages with access to RM1 rodent food (Special Diet Services) and water ad libitum and a 12-hour light/dark cycle. All animal procedures were carried out under Home Office Project license according to the Animal (Scientific) Procedures Act (1986) and after local ethical review.

Treatment of mice

We have previously encountered difficulties, including reluctance of the animals to consume adulterated food and associated toxicities, when administering ethoxyquin (EQ) and butylated hydroxyanisole (BHA) via the diet. In this study, therefore, these compounds were administered by gavage over a shorter period. Adult male hGSTP1::LacZROSA26 mice (8–12 weeks) on an Nrf2+/− or Nrf2−/− background were therefore treated with EQ or BHA by gavage (350 mg/kg body weight in corn oil daily for 2 days). Control groups received vehicle alone. For experiments with 1-aminobenzotriazole (ABT), mice were treated as above but received ABT (50 mg/kg body weight, orally) 2 hours before treatment with EQ or corn oil. Mice were sacrificed by a rising concentration of CO2 24 hours after the final dose. Organs were removed rapidly, rinsed in ice-cold sterile phosphate-buffered saline (PBS) and either snap-frozen in liquid nitrogen for microsome preparation or fixed for LacZ staining. Blood was also collected by cardiac puncture into heparinized tubes. Plasma for biochemical analysis (undertaken by the Clinical Pathology Service, MRC Harwell) was prepared and stored at −20°C until required. hGSTP1::LacZROSA26 Nrf2+/− and hGSTP1::LacZROSA26 Nrf2−/− mice treated with vehicle, EQ, or BHA showed no evidence of alterations in ALT, LDH, creatinine, or glucose levels compared with historical controls, although they did exhibit a small (non-significant) increase in serum bilirubin (data not shown).

![Figure 1. Generation of hGSTP1::LacZROSA26 mice. The construct used to generate the hGSTP1::LacZROSA26 mouse. Approximately 2.6 kb of the human GSTP1 promoter and the entire GSTP1 gene (~2.5 kb) were cloned, fused in-frame with lacZ, into the ROSA26 gene locus by homologous recombination in C57BL/6 embryonic stem cells. Positions of known transcription factor binding sites, and previously reported regulators of gene induction or repression, are shown: cAMP/CRE, NF-xB, RA (32), AP-1/Sp1 (18, 48, 49), insulin (32, 50), p53 (31), and RA/RARE (50).](image)
Preparation of subcellular fractions and immunoblotting

Microsomal and cytosolic fractions were prepared from mouse tissues by differential centrifugation according to standard procedures and protein concentrations were determined using the Bio-Rad Protein Assay Reagent (Bio-Rad). Western blot analysis was carried out loading 5 μg microsomal protein per lane and using polyclonal antiserum raised against β-galactosidase (Sigma), GSTP1 (BD Biosciences), NQO1 (Abcam), GSTA1 and GSTM1 (generous gifts from Prof. J. Hayes), and rat P450s, as described previously (23). GAPDH was used as a loading control (Sigma). Immunoreactive proteins were detected using donkey anti-rabbit horseradish peroxidase IgG (DAKO) as a secondary antibody and visualized by chemiluminescence (ECL+, GE Healthcare) using a Fuji film LAS-3000 mini imaging system (Fujiﬁlm UK Ltd.). Densitometric analysis was performed using Multi Gauge V2.2 software (Fujiﬁlm UK Ltd.).

Tissue sections and LacZ staining

Liver samples were ﬁxed in PBS containing 2 mmol/L MgCl₂ and 1% para-formaldehyde for 3 hours. All other tissues were ﬁxed in Miskys solution overnight. After ﬁxation, samples were washed 3 times in PBS + 2 mmol/L MgCl₂ for 5 minutes and dehydrated overnight in the same solution containing 30% sucrose, embedded in Cryo-M-Bed embedding compound (Bright), and frozen in a dry ice/iso-pentane bath. Cryo-sectioning was performed using a Model OTF Cryostat (Bright) set to −20°C. The samples were equilibrated to chamber temperature for 30 minutes before sectioning. Sections (10 microns) were cut and placed on adhesion slides, rehydrated in PBS + 2 mmol/L MgCl₂ for 5 minutes and incubated overnight at 37°C in X-gal staining solution (PBS + 2 mmol/L MgCl₂, 0.01% sodium deoxycholate, 0.02% Igepal CA630, 5 mmol/L potassium ferricyanide, 5 mmol/L potassium ferrocyanide, and 1 mg/mL 5-bromo-4-chloro-3-indolyl β-D-galactopyranosidase (X-Gal) as a secondary antibody and visualized by chemiluminescence (ECL+, GE Healthcare) using a Fujifilm LAS-3000 mini imaging system (Fujifilm UK Ltd.). Densitometric analysis was performed using Multi Gauge V2.2 software (Fujifilm UK Ltd.).

Preparation of mouse embryo ﬁbroblasts

Embryos were harvested under sterile conditions and skeletal/connective tissue was scissor-minced then trypsinized in PBS for 5 minutes at 37°C. Mouse embryo ﬁbroblast (MEF) medium (DMEM containing 10% FCS, 1% L-glutamine, and 1% penicillin/streptomycin) was added to inactivate the trypsin and the tissue was disaggregated by pipetting before being centrifuged at room temperature for 5 minutes. The pellet was disaggregated in trypsin and incubated for 10 minutes at 37°C, then MEF media was added to inhibit the trypsin before allowing the debris to settle, plating out the supernatant and incubating at 37°C in an atmosphere containing 5% CO₂. Following attachment, the cells were washed with sterile PBS, refed with fresh MEF media, and grown to conﬂuency, at which point they were harvested by trypsinization and passaged onto fresh plates. Cells were not passaged beyond passage 4. Backup stocks were frozen at each passage and stored in 90% FCS/10% DMSO at −80°C.

Induction experiments using MEFs

MEFs (5 × 10⁵ cells/10 cm² dish) were plated in DMEM and allowed to grow for 24 hours before being exposed to fresh medium containing either DMSO (0.1%, v/v) alone or tBHQ (final concentration 20 μmol/L). After up to 24-hour exposure, they were harvested and used for preparation of lysates. Briefly, the cells were washed 3 times in ice-cold PBS and each 10 cm² dish was covered with 300 μL buffer [25 mmol/L Tris HCl pH 7.4 containing 150 mmol/L NaCl, 5 mmol/L EDTA, 1% (v/v) Nonidet 40, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) sodium dodecyl sulfate and complete ULTRA protease inhibitor cocktail (Roche Diagnostics)]. The cells were scraped into an Eppendorf tube and vortexed for 10 seconds, kept on ice for 30 minutes, and centrifuged (16,000 × g for 5 minutes at 4°C). The supernatant was transferred to a clean tube and stored at −80°C. After protein estimation, samples were separated by SDS-PAGE and immunoblotted as described.

Results

Hemizygous hGSTP1::LacZROSA26 mice generated and maintained on a C57BL/6 background were fertile, with normal litter sizes and sex ratios. The transgene was transmitted in a Mendelian fashion and the mice displayed no overt phenotype or welfare issues.

An initial tissue screen characterizing the constitutive expression of the LacZ reporter (and thus hGSTP1) in hGSTP1::LacZROSA26 mice (Fig. 2) revealed that the main sites of reporter expression were the liver, lung, and intestine. In the liver, LacZ staining was only visible in cells in the perportal area (Zone 1), consistent with reporter expression in the biliary epithelium. The LacZ staining observed in the lung was more intense, but this was located almost exclusively in bronchiolar epithelial cells, only occasional cells being stained in the alveolar parenchyma. In the small intestine, constitutive expression was noted in the mid-region of the villus mucosa, but not in every villus. In the large intestine, reporter expression was more uniform from the crypt to top of the villus, but again the pattern of expression was mosaic along the length of the colon. This may reﬂect the role of speciﬁc crypt stem cell populations in generating the mucosal population of the intestinal epithelium or the absence of essential cis-acting elements in certain cell populations, and has been observed in other transgenic reporter models (24, 25).

Low levels of reporter expression were also noted in the gall bladder epithelium, hair follicle, and epidermis and across the whole of the tissue in heart and kidney, where it was punctate in nature. The brain, however, did not exhibit LacZ staining except in the choroid plexus where expression of the reporter was readily detectable, consistent with literature reports on expression of GSTP1 in the human brain (26).
In the light of the above results, and to investigate whether exogenous chemopreventive agents were able to regulate GSTP1 expression in vivo, hGSTP1::LacZROSA26 mice were treated with EQ or BHA and marked changes in reporter expression were observed in the liver, lung, and small and large intestine (Fig. 3A). In the liver, EQ treatment elicited significant LacZ staining in hepatocytes, predominantly in the pericentral (zone 3) region, but also spreading into zone 2. Following BHA administration, although significant induction was observed the effects were less marked than with EQ and were restricted to the pericentral (zone 3) region. Conversely, in the lung, BHA significantly induced expression of the LacZ reporter whereas EQ did not. Pulmonary LacZ staining was almost exclusively restricted to the bronchiolar epithelial cells under both basal and induced conditions, although a small number of cells in the alveolar parenchyma were also positive for reporter gene expression in untreated tissue and this expression increased marginally in response to EQ and BHA treatment. Reporter expression in the small intestine sections was marginally induced by both EQ and BHA (more so by the latter), but remained patchy throughout the tissue and was absent from some regions even after induction. Reporter expression was confined to the mid-region of the villus, punctate staining being observed at the base of the crypt and in the muscularis propria. In the large intestine, patchy reporter expression was detected throughout the length of the tissue (but was uniform along the length of those crypts that were positive) and remained essentially unchanged following EQ and BHA treatment. Western blotting demonstrated that the detection of the reporter, as evidenced by LacZ staining (Fig. 3B), generally reflected the level of expression of both β-galactosidase and hGSTP1 protein in each tissue (Supplementary Fig. S1). However, it should be noted that whereas Western blots involve analysis of an entire tissue, β-galactosidase
staining shows the effects in specific cell types, often resulting in different changes being observed between these 2 methods.

Chemopreventive agents such as BHA and EQ are thought to exert their protective properties through the activation of the transcription factor Nrf2, which in turn induces expression of genes that contain the ARE in their promoters. To clarify the role of the ARE in the induction of the hGSTP1::LacZROSA26 reporter, we crossed the reporter mice onto a Nrf2 knockout background and repeated the induction protocols with EQ and BHA (Fig. 3C). Deletion of Nrf2 had no effect on basal reporter expression in the liver, but resulted in a more marked response after EQ and BHA treatment (1.9- and 2.3-fold, respectively) are consistent with the increased expression observed on the Western blot analysis (Fig. 3B). To establish why deletion of Nrf2 resulted in an increased expression of hGSTP1, we investigated the role of metabolism in EQ-mediated regulation of hGSTP1. Western blot analysis of the hepatic expression of several P450 enzymes following induction by EQ and BHA indicated that treatment with EQ increased the expression of Cyp1a, Cyp2b, and Cyp3a at the protein level but only had a marginal effect, if any, on Cyp2a and Cyp2c expression, whereas BHA only induced the expression of Cyp2b, and to a much lesser extent than EQ. Nrf2 status did not affect this pattern of expression (Fig. 4A and Supplementary Fig. S2). These results suggest that differences between Nrf2+/+ and Nrf2−/− mice in the effects of EQ are not a function of different responsiveness to P450 induction by this antioxidant. However, this does not preclude the possibility that P450-mediated metabolism plays a role in these effects. To investigate this further, we used the cytochrome P450 inhibitor ABT to interfere with the metabolism of EQ and determined the consequences for reporter gene expression. As expected, EQ upregulated reporter expression in hGSTP1::LacZROSA26 Nrf2−/− mice, and reporter induction was more marked on the Nrf2−/− background. In mice treated with ABT or vehicle, hepatic LacZ staining was completely absent, regardless of the presence of Nrf2 (Fig. 4B). However, when EQ treatment was preceded by dosing with ABT, reporter gene induction was severely attenuated, being completely abolished in the absence of Nrf2, whereas only a very few LacZ positive

Figure 3. hGSTP1::LacZROSA26 and hGSTP1::LacZROSA26::Nrf2−/−-basal and induced expression. Adult male hGSTP1::LacZROSA26 and hGSTP1::LacZROSA26 (Nrf2−/−) mice (n = 3) were treated with EQ or BHA (350 mg/kg, orally) or corn-oil vehicle and then sacrificed, tissues removed, and processed for β-galactosidase staining and Western blotting as described in Materials and Methods. Representative sections from liver, lung, small intestine, and large intestine are shown in A (hGSTP1::LacZROSA26) and C (hGSTP1::LacZROSA26::Nrf2−/−). Western blots of pooled microsomal samples against β-galactosidase and hGSTP1 are shown in B. Photomicrographs acquired as detailed in Materials and Methods; bright field, magnification ×10. CO, corn oil.
hepatocytes were found in mice with functional Nrf2 (Fig. 4B). These results indicate that P450-mediated metabolism of EQ is an essential step in the induction of hGSTP1 expression, and also for the activation of Nrf2 by EQ. Biochemical analysis of serum from hGSTP1::LacZROSA26 Nrf2+/+ and hGSTP1::LacZROSA26 Nrf2−/− mice treated with ABT and EQ showed no changes in ALT or glucose levels, but approximately 5-fold increases for LDH, bilirubin, and creatinine following administration of both ABT and EQ (data not shown).

The effects of Nrf2 deletion on the expression of the hGSTP1::LacZROSA26 reporter contrast with the way this deletion affects the expression of other genes [such as hem oxygenase 1 (HO-1)], which are known to be regulated by Nrf2 via the ARE. In our model, induction of HO-1 by EQ and BHA was attenuated and essentially abolished, respectively, in the absence of Nrf2 (Fig. 4A). We went on to investigate the effects of EQ and BHA on expression of other ARE-regulated genes in hGSTP1::LacZROSA26 mice (with or without functional Nrf2) by means of Western blot analysis of NQO1, GSTA1, and GSTM1 in cytosolic fractions from liver, lung, and small and large intestine (Fig. 5 and Supplementary Fig. S3A). Hepatic expression of NQO1 was significantly upregulated by both EQ and BHA in the presence of functional Nrf2 but was not changed above basal values in Nrf2−/− mice; a similar pattern was observed in the other tissues studied (Supplementary Fig. S3B). In the case of GSTM1, basal and induced expression levels in hGSTP1::LacZROSA26 Nrf2+/+ mice were reduced to varying degrees (but not abolished) in liver, lung, and large intestine in the absence of Nrf2.

Figure 4. P450 activity is essential for EQ induction of reporter expression in hGSTP1::LacZROSA26 mice. Adult male hGSTP1::LacZROSA26 mice, wild-type or null for Nrf2 (n = 2 or 3), were treated with EQ (350 mg/kg, orally) with or without pretreatment with ABT (50 mg/kg, orally) or corn-oil vehicle and then sacrificed, tissues removed, and processed for Western blotting using HO-1 and P450 antisera (A) and β-galactosidase staining (B) as described in Materials and Methods. In A, arrow indicates the band for Cyp2b10; B shows representative liver sections. Photomicrographs acquired as detailed in Materials and Methods; bright field, magnification ×10.

Figure 5. Enzyme induction in tissues from hGSTP1::LacZROSA26 ± Nrf2 following treatment with EQ and BHA. Adult male hGSTP1::LacZROSA26 mice, wild-type or null for Nrf2 (n = 3), were treated with EQ or BHA (350 mg/kg, orally) or corn-oil vehicle and then sacrificed, tissues (liver, lung, small intestine, and large intestine) removed and processed for Western blotting using antisera against the proteins shown as described in Materials and Methods. Cytosolic fractions were pooled within a treatment group.
Interestingly, this was not the case in the small intestine. In this tissue, GSTM1 expression was not increased in hGSTP1::LacZROSA26 Nrf2+/+ mice following BHA treatment, but induction by EQ was essentially undiminished and thus seemed to be independent of Nrf2 status. The induction of GSTA1 observed in lung and large intestine of hGSTP1::LacZROSA26 Nrf2+/+ mice following EQ or BHA treatment was completely abolished on the Nrf2+/+ genetic background, although some induction was observed in the liver and small intestine of this genotype after both treatments.

To model the regulation of hGSTP1 and the LacZ reporter by signaling through the ARE, we used tBHQ (the active metabolite of BHA) as an example of a compound that has been shown unequivocally to act via an antioxidant mechanism. The regulation of β-galactosidase (representing the hGSTP1::LacZ reporter), hGSTP1, and various antioxidant response proteins was investigated by Western blotting in MEFs prepared from both hGSTP1::LacZROSA26 Nrf2+/+ and hGSTP1::LacZROSA26 Nrf2–/– mice. Treatment of hGSTP1::LacZROSA26 Nrf2+/+ MEFs with tBHQ led to an increased expression of hGSTP1 at 24 h; this increase was attenuated in fibroblasts derived from Nrf2–/– mice, indicating a role for the ARE in hGSTP regulation (Fig. 6 and Supplementary Fig. S4). The expression of Nrf2 in Nrf2+/+ fibroblasts began to be upregulated within 30 to 50 minutes of exposure, peaked after 4 hours and was beginning to decline by 24 hours. There was also a time-dependent increase in the expression of HO-1, which increased steadily over the first 24 hours of exposure, whereas there was little or no change in NQO-1 expression at the earlier timepoints, increased expression only being detected after 24 hours. In contrast, the expression of NF-κB and ERK1/2 did not change over the 24-hour period of exposure to tBHQ, and while there was increased expression of both c-Jun and c-Fos peaking after 1 hour, the increase was barely detectable in the latter case. When Nrf2–/– fibroblasts were treated in the same way, the pattern of β-galactosidase and hGSTP1 expression was the same as on the Nrf2+/+ background, whereas the expression of Nrf2 was, as expected, below the limit of detection (Supplementary Fig. S4). In contrast with the observations in Nrf2+/+ cells, the expression of NQO-1 was completely abolished in Nrf2–/– fibroblasts, and HO-1 expression was somewhat lower, although it exhibited the same general time course as in Nrf2+/+ cells. Protein quantitation shows the expression profile for c-Fos to be virtually identical in mice with and without functional Nrf2, whereas for c-Jun induction was observed in both genotypes, albeit lower and less sustained in the absence of Nrf2 (Supplementary Fig. S4). The expression of ERK1/2 and NF-κB did not alter from basal levels over the 24-hour period, regardless of the Nrf2 status of the cells. There was no change in expression of β-galactosidase protein in untreated MEFs, or MEFs treated only with DMSO, over the 24 h period (data not shown).

Discussion

We and others have demonstrated that GSTP can play a critical role in both chemically induced and genetically initiated carcinogenesis (11, 13, 27). GSTP is also often overexpressed in human tumors such as lung, colon, and ovary (28). Understanding the endogenous and exogenous factors that control GSTP expression is therefore important in defining those variables that may influence cancer susceptibility and drug response in patients with cancer (2, 29). To that end, we have generated a transgenic mouse model containing the complete sequence of hGSTP together with a LacZ reporter gene to permit histochemical localization of the expressed products of the transgene. The reporter construct contained 2.6 kb of flanking sequence upstream of the GSTP transcription start site, encompassing the reported regulatory elements in the promotor (18, 30) and the entire coding sequence, because regulatory motifs have also been reported in both intronic and exonic regions of the GSTP gene (31, 32). We demonstrate that this model recapitulates the expression profile of hGSTP in vivo, allowing further investigation about the regulation and expression profile of this gene, and providing clues to the endogenous role(s) of GSTP in cellular homeostasis.

Expression of hGSTP1 did not cause any overt phenotypic changes in the hGSTP1::LacZROSA26 mice, which bred normally and exhibited Mendelian inheritance of the transgene. A tissue
screen for β-galactosidase activity found that the reporter gene was expressed to varying degrees throughout the body, in a manner that generally reflected what had been previously reported for expression of hGSTP1 (33). In the livers of hGSTP1::LacZ\textsuperscript{ROSA26} mice, reporter expression was evident around the portal area and in the epithelium of the gall bladder. This corresponds with the restricted expression of hGSTP1 in human biliary epithelium and gall bladder (34, 35), whereas mGstp1/p2 has been reported to be a major isoenzyme in male mouse liver (36). GSTP1 has previously been reported to be the major GST isozyme in human lung (37), being expressed predominantly in the bronchiolar epithelium (38) as observed in this study. Similarly, consistent with our findings, hGSTP1 expression has been reported in both villi and crypts of the small intestine, whereas in the colonic mucosa it was the only GST isoform identifiable (34). LacZ staining was also seen in the epidermis and sebaceous glands of the skin, heart muscle, choroid plexus, and kidney tubules, consistent with the pattern of GSTP1 expression in human tissues (33). In particular, investigation of the expression of GST in human brain has indicated localization to interfaces between blood, brain, and cerebrospinal fluid (CSF), including the choroid plexus, leading to speculation that GSTP might function to protect the brain from oxidant- and CSF-borne toxins (26). These data are also consistent with the expression of hGSTP1 measured by quantitation of RNA across tissues as reported in the BioGPS database (http://biogps.gnf.org; ref. 39).

The pattern of reporter expression in hGSTP1::LacZ\textsuperscript{ROSA26} mice demonstrates the dominant effect of cis-regulatory sequences over the prevalent cellular environment in the regulation of hGSTP1 expression, the distribution observed being more reflective of the human pattern (reflecting the origin of the construct used) than the mouse pattern (determined by trans-acting factors within the mouse cellular environment). Thus, cis-acting elements in the 3′ region of the human GSTP1 gene are sufficient to establish the human pattern of expression. The utility of humanized mice for studying the biologic role of hGSTP1 is illustrated by studies in which a different humanized mouse line was used to address species differences in the toxicity of acetaminophen. When studying the biologic role of hGSTP1 is illustrated by studies in which a different humanized mouse line was used to address species differences in the toxicity of acetaminophen. When hepatotoxicity because of acetaminophen (300 mg/kg, administered either i.p. or orally) was compared in wild-type, mGst1p1/2 null, and GSTP1 humanized mice, the humanized mice exhibited a response that was intermediate between those of the wild-type and null mice, consistent with the expression of hGSTP1 in nonparenchymal cell types (Kupffer cells, endothelial cells, and bile ducts) but not hepatocytes in the humanized line compared with expression in all (or the majority of) hepatocytes in wild-type mice and a complete absence of GSTP in null mice (35). The reporter line we describe will be of utility in the further pursuit of these issues because the construct it contains includes more of the 5′ regulatory region of hGSTP1 and it carries a reporter gene for localization of hGSTP1 expression as well as the complete coding sequence of hGSTP1 for functional studies.

Having established that basal expression of the LacZ reporter in the hGSTP1::LacZ\textsuperscript{ROSA26} mice reflected the expression profile of hGSTP1, we looked at how this expression could be altered in 4 key tissues (liver, lung, small intestine, and large intestine) following treatment with the inducing agents EQ and BHA, both of which have been reported to induce gene expression via the Nrf2/Keap1 system and the ARE (40). Interestingly, however, the induction of reporter expression in both liver and intestine following treatment with EQ or BHA was potentiated by the removal of Nrf2, a phenomenon that contrasted with the attenuated expression and induction of NQO1, and to a lesser extent GSTM1 and GSTA1, in the absence of Nrf2. It is also of note that the induction of oxidative stress in the liver, as measured HO-1 expression, is mediated at least in part by Nrf2, because EQ exhibits both Nrf2-dependent and -independent action. Conversely, pulmonary expression of hGSTP1, as determined by both LacZ staining and immunoblotting for the hGSTP1/βGal fusion protein, was unchanged regardless of Nrf2 genotype. It is interesting to note that both basal and induced expression of NQO1, GSTM1, and GSTA1 in the lung was severely attenuated in the absence of Nrf2 (Supplementary Fig. S3A and S3B). This may indicate, either that the ARE does not play a significant role in regulating the expression of hGSTP1, and/or that pulmonary expression is already at maximal levels, possibly because of a critical role played by the enzyme in this tissue (11, 41).

There are several possible explanations for these findings; for example, Nrf2 may not regulate expression of hGSTP1 directly; instead it may affect levels of an enzyme involved in the metabolism of EQ and BHA or their derivatives. In the absence of Nrf2, altered metabolism could lead to the accumulation of one or more metabolites that, in turn, result in increased hGSTP1 induction through other regulatory elements such as AP-1 or NF-kB. These data are interesting as they illustrate not only that chemopreventive agents exert their effects by multiple pathways in addition to their effects on Nrf2 signaling, but also that GSTP is regulated in vivo by cellular stress pathways such as AP-1, independent of Nrf2. Our experiments with ABT demonstrate that at least 2 mechanisms are involved in transgene (and hence hGSTP1) induction by EQ and that one of them requires P450-mediated metabolic activation. Although the identity of the P450(s) involved is unclear, it is likely to involve members of the Cyp2b family, because EQ upregulated the expression of Cyp2b10 in our experiments and has previously been shown to strongly induce the de-ethylation of benzoxylresorufin (42). Furthermore, microarray analysis of mouse liver following EQ administration revealed a gene expression profile similar to that observed following phenobarbital treatment: the expression of 70 genes was increased at least 2-fold in response to PB and 23 of these were also upregulated to a similar extent following treatment with EQ (unpublished). The most likely explanation for the potentiation of GSTP expression in Nrf2\textsuperscript{-/-} mice is that both EQ and BHA activate other signaling cascades, such as AP-1 signaling, and that as a consequence of the attenuation of the antioxidant Nrf2 response these stress response pathways are further induced.

It is clear from our in vitro data that tBHQ is capable of inducing the expression of hGSTP1 and that this is compromised by the absence of Nrf2, at least in vitro, suggesting that Nrf2 can regulate expression of hGSTP via the ARE (Fig. 6 and
Supplementary Fig. S4). Loss of Nrf2 may allow other transcription factors (e.g., Fos and Jun) to access the embedded AP-1 site within the ARE (43), thus increasing gene expression. The contrast between in vitro and in vivo findings with regard to increased expression in the absence of Nrf2 may be because of a lack of the relevant transcription factor(s) in the MEF system. These data differ from those in a previous report stating that tBHQ and sulforaphane fail to induce hGSTP expression in HaCaT cells (44). These differences may simply reflect the different models used: HaCaT is a transformed human keratinocyte cell line and may lack essential metabolic and/or regulatory factors required for induction by tBHQ and sulforaphane.

There has been intense debate about the consensus sequence of the ARE, which apparently varies in terms of sequence, numbers of elements, and genomic organization not only between species but also between genes within the same organism (19, 45, 46). Although a simple definition of the ARE is not possible, Hayes and colleagues (20) have argued that the variable context and content of the ARE lends itself to recognizing 4 classes of enhancer element:

- **Classes 1 and 2** contain the 16 bp extended ARE (5'-TAMAnnTRGAYnnnGR-3', where M = A/C, R = A/G, and Y = C/T and the 9 bp core ARE is in bold), with or without an embedded AP-1 site (underlined), respectively.
- **Classes 3 and 4** contain a minimal ARE (5'-RTGAYnnnGR-3'), with or without an embedded AP-1 site (underlined), respectively.

Examination of GSTP promoters in mouse, rat, and human reveals an ARE within the first 150 bp upstream of the transcription start site in each case; the rodent sequences consist of a 9 bp core with an embedded AP-1 site, whereas the transcription start site in each case; the rodent sequences reveals an ARE within the first 150 bp upstream of the ATG. This has been termed the GPEI (47) and comprises a class 1 ARE. The human GSTP gene has another ARE at approximately −2,166 bp (44).

In summary, we have generated a transgenic mouse model that recapitulates the expression profile of hGSTP in vivo, and shown that cellular levels of human GSTP can be profoundly affected in vivo by environmental factors in a predominantly Nrf2-independent manner. These data demonstrate how dietary components and other exogenous factors may, through modulation of GSTP levels, affect cancer susceptibility and thus potentially the outcome of chemotherapy. The hGSTP1::LacZROSA26 model will also be a valuable tool with which to investigate the endogenous role(s) of GSTP in cellular homeostasis, response to toxic insults and mechanisms of carcinogenesis.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Authors’ Contributions**

Conception and design: C.J. Henderson, C.R. Wolf

Development of methodology: A.W. McLaren, C.R. Wolf

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): C.J. Henderson, A.W. McLaren

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): C.J. Henderson, A.W. McLaren, C.R. Wolf

Writing, review, and/or revision of the manuscript: C.J. Henderson, C.R. Wolf

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): A.W. McLaren

Study supervision: C.J. Henderson, C.R. Wolf

**Grant Support**

C.R. Wolf is supported by a Cancer Research UK Programme Grant C4639/A10822.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received March 19, 2014; revised April 27, 2014; accepted May 3, 2014; published OnlineFirst June 16, 2014.

**References**


In Vivo Regulation of Human Glutathione Transferase GSTP by Chemopreventive Agents

Colin J. Henderson, Aileen W. McLaren and C. Roland Wolf

Cancer Res  Published OnlineFirst June 16, 2014.

Updated version

Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-14-0792

Supplementary Material

Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2014/06/16/0008-5472.CAN-14-0792.DC1

E-mail alerts

Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.